India-US trade deal: Interim pact brings ‘certainty and clarity’ for pharma sector
NEW DELHI: The interim India-US trade arrangement provides certainty and clarity to the domestic pharma sector, with medicines staying outside reciprocal tariffs, and Washington signalling negotiated treatment for generics under Section 232.India plays a critical role in supplying affordable medicines to the US, with shipments of around $10 billion accounting for nearly 35% of its…